
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 688670.SS and 80,000+ other tickers.
See exactly how 688670.SS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 688670.SS and 80,000+ other tickers.
Jiangsu gdk Biotechnology Co., Ltd. operates as a biotechnology firm specializing in the comprehensive research, development, manufacturing, and commercialization of human vaccines, alongside providing related services. Its current portfolio includes a quadrivalent split-virus influenza vaccine and a lyophilized human rabies vaccine. The company's pipeline is strategically focused on preventing major infectious diseases such as influenza, rabies, chickenpox, shingles, and pneumonia. This enterprise was established in 2008 and is headquartered in Taizhou, China.
No recent news available.